was funded by EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Novo Nordisk Rising Star 2024 and IBSA Foundation Fellowship Endocrinology 2023
Switching from cyanocobalamin to methylcobalamin or hydroxocobalamin formulations eliminates the flushing in most cases, as these forms don't trigger the same mast cell degranulation pathway
Key takeaways New GLP-1 drugs are coming onto the market in 2026 and beyond These new products could widen up GLP-1 drugs to a much larger and different audience: creating an even bigger impact on F&B than seen to date and shifting who core users are New drugs could also have different impacts on how people react to food and drink: and therefore what they want and need from products
FAQs How do you microdose with GLP-1
Conversely, Exendin-4 appears to mitigate anxiety-like behaviors in the Her + Ex-4 group, potentially due to an increase in the number of glutamatergic neurons within the BLA region of these mice
Its stalling because prior auth policies still live in PDFs, workflows werent designed for real-time decisions, testing across payers and delegated partners is fragmented, and reporting will be required before the plumbing is fully in place